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but with ~e number of lesion~ dilated and with a less effeClk~ initial dillon. 
Severe mstsnosls (>. 70%) was an important driving force for a~itiona] 
procures. 
2:30 
The Iml~Ct of the Comple~neu of 
....... gevncmaf l s I t lon  o,, Adverse Cardiac Events at 1 
year Follow-Up In 1021 CABRI Pstlents 
Ame Bree l ,  Erie Boarsmtl, Jaap W. Dedmrs, Patrick W. Sernsys on 
behalf of Ihe CABRI investigators. University Hosplta/Rotlerdam. The 
Netheflar~ 
Baokground. The Major Adverse CaKli~c Events (MACE: death, myocartlial 
infarclion (MI), GABG and PTCA) ~ 1 year foll0w.up of lhe Coronary An* 
gtoplaMy Bypass Revas~leurisation Investigation (CABRI) were previously 
reported. Overall results: no significant d~emnce in sutvlval and MI rate, 
but a slgniticarttly higher e.intarve~on rate in I~tie~; randomised to PTCA 
relative to CABG. We studied ~te ~e,~ of ~mpletsnas~ of revasculmisati~n 
on MACE at I year foil¢:.w-up. 
~; ,  Patients randomised to PTCA, were divided in 4 glo~ps: (I) 
~omplete rev~,cularisatlon (prooedural result: 0 vessel dmease (VO), n = 
154), (11) nearly =replete (1 VD, n ~ 210), (111) nearly in¢ompleta (2 VD, n 
- 75) and (IV) inoomptete revaec~.~tion (2or 3 VD unchanged, n= 94). 
Kaplan-Meiar event~fme SUndVal o~rve~ were cal~Jlated. 




Oeath, MI, CAIZG 
0eath, MI, CAI~I, FTGA 
95 97 9~ 96 0.e 
92 94 93 90 e.4 
~7 84 75 59 o.0o01 
64 47 49 0.0001 
Conclusion. (1) The complets~ess of mvasCUladsatlen was not predic- 
tive of survival or MI. (2) The re.intervention rate is ~ function ef the 
(in)oompleteness of ¢evas~ularisatlon. 
2:45 
~ compmaflve 5 Year Inddence of IscJlemlo Events 
for PTCA and CABG in the ~ Ar~l lOp~My 
Rovasculerizetion invesUgMion (BARI) 
Bernard R. Chairman, Leonard S~hwa~z, ~ $. Roubin, Bru~e W, Lyric, 
Regina M. Hardison, George Solg..o, David O. Williams, PdcJrla~ S. Stack, 
Nicl~olas 1". Kouchoukas, Mide A. Kelletl, and the BARI Investiga~rs. ~/. 
LoUis Unlve;s~ .Sc hool of Medicine, ~, Lou~, MO 
The By~t.ss ~ngioplasty Revas~ladZatton I ~n (BARI) examine0 
the hypothasis that an initial revas~uladza~e, strategy of ~ u s  trans- 
iumi~ coronary angieptamy (PTGA) eompar~ to com~ ~m~'y ~imss 
graft (CABG) surge~/in pts with multiveS~el mronaty disease does not com- 
promise clinical outcome d~dng 5 year IOllew.up. Belween August. 198~ and 
August, 19~1,914 and 91S pts were randomly asalgn~d to CABG or PTCA 
at 18 med,=~l Centers. Ascerlalnment ofisd~emi~  enamts ~ere 1~:~ 
on serial EGG muWsls, ~ enzyme data, clinical history, and daSsifie~d 
at the St. Louis University (:ore laboratory. The events were dassltied as my- 
0Caldtal InfuSion (MI) if ~y  of the f0110Wktl~ events o~urmd; (1.) a 2 grade 
Minnesota code Q-wave pfogms,sion, (2,) new left bundle branch bfock w;th 
abnormal ~ l tac  ram/rues or (3.) abnormal cardia~ enzymes ~md the= paln 
>_ 20 mim.~s or womening of ST-T wsve ~0oom~ttes. ~ were clas- 
sified as Ischemic but nonlnfarct if me abnve ~it~da were nof mat, can~lac 
enz,~'~es w~e nomml, and the i~ had or, era p~. > ~ minmes, mqui~l 
a hospitat visit, ~ had the new ou~werce of ST-T wave abnormalill~, 
¢,nu~Jn:~ wiv~l ra~s Lq the FrcA ~md CABG groups. "the rotes were 
exaldned in a pdod sUb(itoups of ~ angtn~ (69% of gte population). 
sevm deronk: m=~,. ar~li.a (t6%), tool mild o~ no ang~ I~ sevee is- 
~m~ on ,onlnvae,~ee testing (1S%), The ra~ were ~ I. pt ~P.~,~ 
mrat~l ~ num~ of ~ ,~ vemm~  loft v ~  ~ ~mmon0 
50%, Itypemms~, dtabms, em~ ~ I~m~t ~amm~. Results m~ t~ 
pe=m~d. 
3:00 
~ Clinical Out¢~ome and Costs of CABG and PTCA in 
' the GABI Study Over 2 Years Follow.Up 
C.,hdslJan W. Harem, Peter I(alm~. Jac~'bUS Reirners, 
Hans-J0rg~ Ru~.ht .  Chtistoph Schrn~, "iltornas Ischinger, and the 
GABI Study Group, Oepr of C.ar~1~, a~ Carc~ Surgery. University 
Hospi~ Eppendo#,, Ham~rg. Genna.y 
In the German Anglol3as;y l~ypass-Surgery Investigation (GABI) 359 patients 
(lots) with ~ t i ¢  multives.~sl disease (MVD) ~ 'e  ra~domizad toCABG 
(n = 177) and I~'CA (n = 18~.) dudng 1986 and 1991. There was no difference 
LP~.tweem the fwo t re~ ~lP ,  ieS with respect o the efficacy on arcjina 
pectorl~ relief at I and 2 years follow-r~ ('i% vs. 10% CC~ >_ 3). However, 
retnterventiens i  PTCA pts were morn ~'equent (44% vs 6%, p < 0.001 )and 
21% pts oossed ov~" to GABEi dudng the first year. In the second year. the 
reintewention r~e was only 4% (CABG) arKI 5% (PTCA). Inilial and follow. 
up costs were compared a~ording to the ~urrent pr~e index. Proced~rral 
co.~s were calculated based on 50 pts undargo~ng MVI~ABG and ~ pt~ 
undergoing single or k'ND PTGA. Gems of MVD-PTCA were $8.200 (62% 
material, 13% personnel, 5% roo.~tng) and of CABG $19.200 (51P/. material, 
37% penmn~l, 6% morning). Averaged costs per patient dudng follow ~:  
. . . . . . . . . . . . . . . . .  ,c~_~...!=)_. F rC~m . . . . . . .  
~ = ~ n  ~9~ 9900 
S nvom~ ~9C~00 t2f~0 
1 year 19/00 14600 
Conclusions: CABG ar¢l PTCA in MVO ~re equally efteclk~ in re,~tudng 
angina over 2 year~, Initial costs of PTCA are 49% lower, Due to minter- 
ve~ons in lhe first year, costs increase to 76 % of CABG ¢ :sts  after 2 
years. 
3:1 5 
Ihx lmal  Benefit of Integ~+in ~ le t  liB/Ilia 
- -  Blockade 6.-24 Hem Alter Therapy: Re~ults of the 
IMPACT~ Trial 
Mark C,G. Ho,'figan, J~  E. rcheng, Robe~ M. C.aFdf, Michael 
Todd Lorenz, Kdstina ~t~mon. A M~hael LincoW, Eric J. Topoi, for the 
IMPACT-II Inves~ab~. ~ of ~ Cleveland Clinic 
Fou~,  G/eve/and, OH 
The IMPACT.It ~ con~ high and Iron ¢k~;e infusions of the peptk~ 
lib/ilia inlttbitor Integmlin with ~a~ebo in 4,010 patients undergoinQ o~ronan] 
intervention, integralin Provides ¢onttnuous a~i ta le t  eltect for ~ din'alien 
cf infusion (median 21 ICmrs). ~ plbtlaTy endpcdnt was a comIxc#te of 
death, in~axt~on, ~ ul~'ettt ~.~intmve,A~orl (PTC, A, s,"¢,',,~ k-/p¢~.~ .t ~,~j/) at 
30 days; ~ ,  76% of avents ~ ~ithin 24 hQu~s of entpj. K ,~*  
Meter analy~ds showed a maximal differercu in endpa~ fre~.emcy between 
pla¢~o and Integtelin ~oup~ oo~ 10~v~en 6 ~nd 24 bouts (P = 0.013), 
and ~t  ~ magn~ude was reecced at 30 days (P = 0.063). There was no 
o~temrce in alllc~-y be~veen t~ and tow do~ therapy. 
. . . . .  . . . . . . . . . . .  
Fre~ of MI w~ mdLCed by up to 22% in the intsgrelin~trea~¢l groups 
(P ~, 0,0S) ~ 30 daW, Need tot urgem re-lntepm~ion was sig~caofly re- 
duced as smly as 3 I~s  (60% reduction; P < 0.02) In pa~e~ re:airing 
e.teWerm; the~ d~ererces deo'eased to *-'0% 0~gh dose) a,d 27% 0ow 
dose); P = 0.190 and 0,06~ mspe~,  by 30 days. Aftsr Integn~m liter - 
ap~, major redu=~ ~ ~d~ evares was obsew~ wte~ 24 .~ .  of 
e~.  Maxtm~ bene~ ~ eaey and wes pre~ranan~ me~e~ by 
~ tn me inc id~ of n'~*,T.~i ~ "11~ ~ect was somewhat 
~n~tmd by the end of the ~1 ~v-up  pe~.  
